New Pharmaceuticals market report from Global Markets Direct: "Bone Metastasis - Pipeline Review, H2 2013"

Boston, MA -- (SBWire) -- 09/24/2013 --Global Markets Direct's, 'Bone Metastasis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Bone Metastasis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bone Metastasis. Bone Metastasis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

View Full Report Details and Table of Contents

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Bone Metastasis.
- A review of the Bone Metastasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Bone Metastasis pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to Get This Report

- Identify and understand important and diverse types of therapeutics under development for Bone Metastasis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Bone Metastasis pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Companies Mentioned in this Report: Johnson & Johnson, Celsion Corporation, Amgen Inc., Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Bayer AG, Medivir AB, Osteologix, Inc., Transgene SA, Green Cross Corporation, Merrion Pharmaceuticals Plc, Digna Biotech, S.L., Debiopharm Group, Amura Holdings Ltd., Alethia Biotherapeutics Inc., Deciphera Pharmaceuticals, LLC, Targa Therapeutics Corp., America Stem Cell, Inc.

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- Bone Metastasis - Pipeline Review, H1 2013
- Bone Disorders - Pipeline Review, H2 2013
- Bone Marrow Transplantation - Pipeline Review, H2 2013
- Brain Metastasis - Pipeline Review, H2 2013
- Osteoporosis - Pipeline Review, H2 2013
- Osteoarthritis - Pipeline Review, H2 2013
- Rheumatoid Arthritis - Pipeline Review, H2 2013
- Arthritis - Pipeline Review, H2 2013
- Bone Metastasis Global Clinical Trials Review, H1, 2013
- Stroke - Pipeline Review, H2 2013